Anders Pedersen
Chief Operating Officer bei GALECTO, INC.
Vermögen: 2 922 $ am 31.03.2024
Profil
Anders H.
Pedersen is the founder of Profound Pharma AS, which was founded in 1999.
He held the title of Director-Protein Chemistry from 1999 to 2009.
Currently, he is the Chief Operating Officer at Galecto Biotech ApS since 2013 and at Galecto, Inc. since 2020.
In the past, he worked as a Manager-Projects & Department at Novo Nordisk A, Principal at The University of New Mexico, Senior Vice President-Development at AGC Biologics A, Chief Operating Officer at Recepticon ApS, and Vice President-Portfolio Management at Life Cycle Pharma A.
He also worked as a Manager-Project & Department at Biotech.
Mr. Pedersen received his undergraduate degree from the Technical University of Denmark.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GALECTO, INC.
0,01% | 04.01.2023 | 3 746 ( 0,01% ) | 2 922 $ | 31.03.2024 |
Aktive Positionen von Anders Pedersen
| Unternehmen | Position | Beginn |
|---|---|---|
| GALECTO, INC. | Chief Operating Officer | 01.01.2020 |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Chief Operating Officer | 01.01.2013 |
Ehemalige bekannte Positionen von Anders Pedersen
| Unternehmen | Position | Ende |
|---|---|---|
AGC Biologics A/S
 AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Corporate Officer/Principal | 01.03.2013 |
Recepticon ApS
 Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | Chief Operating Officer | 01.11.2009 |
| Life Cycle Pharma A/S | Corporate Officer/Principal | 01.11.2006 |
| The University of New Mexico | Corporate Officer/Principal | 01.01.1990 |
Profound Pharma AS
 Profound Pharma AS Pharmaceuticals: MajorHealth Technology Profound Pharma AS provides pharmaceutical products. The Danish company was founded by Jan Møller Mikkelsen, Anders H. Pedersen, Hans Thalsgård Schambye. Profound Pharma was acquired by Maxygen, Inc. on August 10, 2000 for $69.46 million. | Founder | - |
Ausbildung von Anders Pedersen
| Technical University of Denmark | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| GALECTO, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Profound Pharma AS
Profound Pharma AS Pharmaceuticals: MajorHealth Technology Profound Pharma AS provides pharmaceutical products. The Danish company was founded by Jan Møller Mikkelsen, Anders H. Pedersen, Hans Thalsgård Schambye. Profound Pharma was acquired by Maxygen, Inc. on August 10, 2000 for $69.46 million. | Health Technology |
AGC Biologics A/S
AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Health Technology |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | Health Technology |
Biotech
 Biotech BiotechnologyHealth Technology The private company manufactures biotechnical products. The company is based in Cambridge, MA. | Health Technology |
| Life Cycle Pharma A/S | |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
